- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
3T Head-Only MRI System Gets FDA Clearance
The Signa Magnus MRI device offers a slew rate and gradient amplitude that are reportedly superior to those of 60 or 70 cm bore whole-body MRI systems.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Signa Magnus system, a 3T magnetic resonance imaging (MRI) system for head-only scanning.
Featuring HyperG gradient technology, the Signa Magnus system facilitates faster MRI scanning with performance levels of 300 mT/m and 750 T/m/s, according to GE HealthCare, the manufacturer of the system. In addition to shorter scan times, the company said the neuroimaging system offers advanced diffusion imaging capabilities and a high signal-to-noise ratio (SNR).
GE HealthCare said the head-only emphasis of the newly FDA-cleared Signa Magnus 3T MRI system facilitates a gradient amplitude and slew rate that exceed those of conventional whole-body MRI platforms. (Image courtesy of GE HealthCare.)
Noting an asymmetrical design that shifts the gradient isocenter to the patient edge of the coil, GE HealthCare said the head-only emphasis of the system facilitates a gradient amplitude and slew rate that exceed those of conventional whole-body MRI platforms.
“We're very excited about the capabilities Signa Magnus provides,” said Kawin Setsompop, Ph.D., an associate professor of radiology at Stanford University. “I plan to leverage the gradient performance to look at microstructures with diffusion imaging, such as axonal diameter. Additionally, using the high slew rate for efficient readout in terms of EPI and spiral to sample k-space faster will help achieve higher resolution with fewer artifacts.”
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
